• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AptarGroup Stock In Focus After Earnings Results And Pharma Margin Improvement

    Simply Wall St·11/02/2026 11:19:18
    Listen to the news
    • AptarGroup reported third quarter 2026 sales of US$1,019.12 million, with net income of US$32.6 million and diluted EPS of US$0.51, alongside a higher dividend and ongoing share repurchases.
    • The earnings release highlighted underlying margin improvement in AptarGroup’s Pharma segment, a key business that serves a customer base heavily weighted to Europe.
    • This article reviews how AptarGroup’s investment narrative is influenced by the Pharma margin improvement highlighted in the latest quarterly results.

    Scan how AptarGroup’s latest earnings, dividend move and buybacks compare with peers by reviewing a curated set of list of solid balance sheet and fundamentals (24 results).

    AptarGroup Investment Narrative Recap

    To own AptarGroup, you need to believe that the high margin Pharma platform remains the anchor, while Beauty and Closures gradually become less of a drag. The latest quarter shows that mix clearly. Sales were higher, yet net income and EPS were meaningfully lower, so near term pressure on profitability is still real.

    The key short term swing factor is whether Pharma margin improvement can offset emergency medicine destocking and weaker North America Beauty and Closures performance. Legal expenses and a higher debt load add another layer of risk. The earnings reset is material and keeps execution around cost control and mix in sharp focus.

    The most relevant fresh data point is the third quarter 2026 earnings report. Sales reached US$1,019.12 million, compared with US$961.13 million a year earlier, while net income moved to US$32.6 million from US$127.93 million, with diluted EPS at US$0.51 from US$1.92. That is a significant compression in profitability.

    For investors, the link back to catalysts is straightforward. Pharma’s underlying margin progress aligns with the long term story around injectables, integrated services and inhalation platforms. At the same time, the drop in group profitability, emergency medicine destocking and ongoing Beauty and Closures issues keep the downside scenario around earnings and returns highly visible.

    AptarGroup’s analyst framework points to forecast revenues of US$4.6 billion and earnings of US$470.6 million by 2029, based on 5.3% yearly revenue growth and an earnings increase of about US$108 million from current earnings of US$362.5 million.

    Uncover how AptarGroup's fair value indicates an 18% potential upside to its current price before sentiment closes that discount.

    NYSE:ATR 1-Year Stock Price Chart
    NYSE:ATR 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate angle on AptarGroup focuses less on Pharma margin progress and more on the risk that emergency medicine and nasal decongestant demand keeps normalizing. The most cautious analysts were only penciling in about US$4.4b of revenue and US$443.6 million of earnings by 2029. That is a much more pessimistic path than consensus, and the latest earnings and dividend news may pull those views closer together or push them further apart.

    Explore 3 other AptarGroup fair value estimates, including one that suggests it could be worth just $135.00.

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

    Looking for more AptarGroup sized investment ideas?

    If this AptarGroup review sharpened your thinking and you want to broaden your watchlist, the Simply Wall St Screener can help you line up other stocks with fundamentals that fit your style.

    • For investors who want potential upside without ignoring quality, you can filter for companies that combine strong cash flows with supportive balance sheets using the 36 high quality undervalued stocks.
    • If capital preservation sits high on your priority list, you can focus on companies with steadier risk profiles by running the 29 resilient stocks with low risk scores.
    • To widen the opportunity set beyond well known tickers, you can surface lesser known companies with solid metrics by scanning the 19 high quality undiscovered gems.